Quantitative Benefit–Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis

In the early SARS-CoV-2 (COVID-19) pandemic, four major vaccines were approved despite limited efficacy and safety data through short regulatory review periods. Thus, it is necessary to assess the benefit-risk (BR) profiles of the COVID-19 vaccines. We conducted a quantitative BR assessment for four...

Descripción completa

Detalles Bibliográficos
Autores principales: Son, Kyung-Hwa, Kwon, Sun-Hong, Na, Hye-Jung, Baek, Youngsuk, Kim, Inok, Lee, Eui-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785565/
https://www.ncbi.nlm.nih.gov/pubmed/36560439
http://dx.doi.org/10.3390/vaccines10122029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785565/
https://www.ncbi.nlm.nih.gov/pubmed/36560439
http://dx.doi.org/10.3390/vaccines10122029

Ejemplares similares